Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals Plc LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -19.00 -0.86% 2,180.00 2,190.00 2,195.00 2,227.00 2,157.00 2,186.00 942,439 16:35:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1,661.1 370.2 151.4 13.4 5,275

Hikma Pharmaceuticals Share Discussion Threads

Showing 1101 to 1124 of 1125 messages
Chat Pages: 45  44  43  42  41  40  39  38  37  36  35  34  Older
DateSubjectAuthorDiscuss
02/4/2020
11:59
Yertiz - totally agree. Wish I had more! Suet
suetballs
02/4/2020
09:51
Safe, solid investment in the current climate. Not too many like Hikma around at present.
yertiz
20/3/2020
07:39
the link shows many companies but not hik
ali47fish
06/3/2020
10:33
Why we continue to view Hikma as an excellent stock to hold for long-term dividend growth: hxxps://www.investorschampion.com/channel/portfolio/results-roundup-high-yielders-still-delivering
investorschampion
05/3/2020
05:11
Expect this one to hit £30 over next year....
robertball
27/2/2020
09:50
Nice share price rise too. Suet
suetballs
27/2/2020
07:58
Nice 2019 result. Suet
suetballs
18/12/2019
15:13
lovely rise - passed the 50DMA
itsnotmeitsy0u
13/12/2019
09:18
bought in today at 18.98 excellent long term prospects
gilesy
20/11/2019
11:22
Update from our Income Boosters portfolio after a strong third quarter, which includes Hikma. Find out more here hxxps://www.investorschampion.com/channel/portfolio/dividend-diamonds-our-income-stocks-continue-to-deliver-solid-results
investorschampion
07/11/2019
11:58
Hikma Pharmaceuticals said it expected revenues in its generics business to be closer to the top end of its guidance range following strong demand and operational improvements. For the full year, the pharma company said it now expected generics revenue to be closer to the top end of its guidance range of $690m to $720M and continued to expect core operating margin to be in the range of 16% to 18%. For its injectables business revenue guidance was maintained in the range of $870m to $900m for the full year in 2019 and core operating margin in the range of 36% to 38%. Its injectables business in the US had experienced good demand, which more than offset increased competition and the gradual decline in revenue from shortages of pain management products, as expected. Its branded business, meanwhile, benefitted from 'strong growth' in most markets more than offsetting lower sales in Algeria. 'We continue to expect branded revenue growth in constant currency to be in the mid-single digits for the full year in 2019,' the company said.
broadwood
07/11/2019
10:22
profit taking???
robertball
30/8/2019
12:44
Hikma has yo-yoed in and out of the FTSE 100 twice already this year and many more times in previous years. Will Hikma retain its place in the September FTSE shuffle? Here are our predictions of who is in and who is out of the premium index hxxps://www.investorschampion.com/channel/blog/ftse-shuffle-september-promotions-and-demotions
investorschampion
29/8/2019
12:04
Any idea when the Advair generic resubmission is expected....time's ticking on.
fhmktg
09/8/2019
15:34
lets see if there is a late rally for your 10% rise fingers crossed
red5
09/8/2019
15:22
019 | 09:14am - Hikma Pharmaceuticals said it had signed an asset purchase agreement with Insys Therapeutics to acquire a complementary manufacturing platform and two pipeline products. Hikma acquired unit-dose nasal and sublingual spray manufacturing equipment, as well as two pipeline products, naloxone 505(b)2 nasal spray and epinephrine 505(b)2 nasal spray after Insys was forced to sell its assets after initiating Chapter 11 of the US Bankruptcy Code. Naloxone is a medication used to block or reverse the effect of opioide, whel epinephrine is a medication used to treat a number of conditions, including anaphylaxis, cardiac arrest, and superficial bleeding. The announcement comes as the company raised its outlook for its injectables and generics businesses after reporting strong sales in the first half of the year thanks to the launch of new products.
broadwood
09/8/2019
08:12
Rocketing. End of day + 10% ??
broadwood
09/8/2019
07:52
Hikma Pharmaceuticals upgrades outlook amid 'strong' sales in H1 Just what the doctor ordered. StockMarketWire.com - Hikma Pharmaceuticals raised its outlook for its injectables and generics businesses after reporting strong sales in the first half of the year thanks to the launch of new products. The company said it expected full-year Injectables revenue to be in the range of $870m to $900m and core operating margin to be in the range of 36% to 38%. Generics revenue for the full year was expected to be in the range of $690m to $720m, with core operating margin in the range of 16% to 18%. Branded revenue, meanwhile, was expected to be higher in the second half of the year and with revenue growth in constant currency to be in the mid-single digits. The upgraded outlook comes as the company saw profits jumped on the back of an increase in revenues. For the six months ended 30 June 2019, pre-tax profits rose to $226m from $141m a year earlier and revenue grew 8% to $1,047m, reflecting 'strong sales of our in-market products and new product launches,' the company said. The interim dividend was raised by 17% to 14 cents per share.
broadwood
09/8/2019
07:52
Nice results
joshuam
27/6/2019
14:15
And again. My 1358 buy showing as a sell on ADVFN.
bantam175
20/6/2019
10:09
That 1600 was a sell not a buy. ADVFN got it wrong again.
bantam175
03/6/2019
09:54
Good recommendation? https://www.fool.co.uk/investing/2019/06/01/top-shares-for-june-2019/
bantam175
31/5/2019
10:47
Whats happening?
joel erickson
17/5/2019
07:48
StockMarketWire.com - Hikma Pharmaceuticals said it was on track to meet full-year expectations following a 'good start' to the year, driven by recent product launches and good demand across all three businesses for its products. Its injectables business was performing well, as strong product demand in the US, more than offsetting increased competition. In MENA and Europe, Its injectables businesses were on track to deliver 'good growth this year, particularly in our top MENA markets,' the company said. 'We continue to expect global Injectables revenue to be in the range of $850 million to $900 million in 2019,' it added.'We expect core operating margin to be in the range of 35% to 38%.' In its generics business, the company reiterated its guidance for revenue in the range of $650m to $700m in 2019. Branded revenue growth, meanwhile, was expected to be in the mid-single digits in constant currency in 2019. 'We have been building on this momentum and 2019 is off to a good start. Across our three businesses, we are driving good demand for our broad product portfolio and recent product launches,' said Siggi Olafsson, Hikma's CEO. 'We continue to strengthen our capabilities, pipeline and business operations, whilst maintaining our focus on cost reduction. I am pleased to reiterate our full year guidance for 2019 and we remain confident in the outlook for the Group and our ability to deliver long-term, sustainable growth.'
broadwood
Chat Pages: 45  44  43  42  41  40  39  38  37  36  35  34  Older
ADVFN Advertorial
Your Recent History
LSE
HIK
Hikma Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200408 22:44:01